CPT Editorial Panel approved the addition of new product codes

Beginning on Aug. 14, 2023, the CPT Editorial Panel approved the addition of new product codes 91318-91322 (91318 , 91319 , 91320 , 91321 , 91322) to identify monovalent vaccine product for immunization against COVID-19 (Pfizer, Moderna); retained existing Novavax Product Code 91304 for currently authorized vaccine product available for use in the U.S. and the updated (XBB.1.5) vaccine; deletion and/or revision of all other existing COVID codes (product and administration with associated guidelines and parenthetical note deletions/revisions); and addition of a single administration code (90480) for administration of new (i.e., 91318-91322) and existing (i.e., 91304) COVID-19 vaccine product.

All existing CPT codes that describe COVID-19 vaccine products and associated administration codes that end in “A” for products that are no longer covered under an existing Emergency Use Authorization (EUA) or Biologics License Application (BLA) from the US Food and Drug Administration (FDA) will be deleted effective Nov. 1, 2023.

Source: https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes